Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

Inclusion Criteria: * Diagnosis of steroid refractory aGVHD defined as no response to methylprednisolone at 2 mg/kg for 1 week or disease progression after 72 hours of methylprednisolone at this dose. Potential subject will have had no decrease in any GVHD organ staging as follows: * Skin rash, if present, does not decrease by one stage. This is based on the percent of the body involved with rash, plus presence of bullae and desquamation. * Gut GVHD, if present, does not decrease by one stage. This is based on volume of diarrhea, pain, and ileus. * Upper gastrointestinal GVHD, if present, does not resolve. * Liver GVHD, if present, does not decrease by one stage. This is based on total bilirubin level. * Prior allogeneic hematopoietic stem cell transplantation using bone marrow, peripheral blood or umbilical cord cells. Recipients of standard as well as nonmyeloablative transplants are eligible. * No previous immune suppressive therapy given for treatment of acute GVHD except for corticosteroids. * Absolute neutrophil count greater than 0.5x106/L. * Estimated creatinine clearance greater than 30 mL/minute. * Written informed consent Exclusion Criteria: * Patient receiving either infliximab or daclizumab within seven days of study. * Patient with uncontrolled infections will be excluded. * Patients receiving other investigational agents for GVHD prophylaxis or treatment. * Patients with congestive heart failure. * Patients with history of intolerance/ hypersensitivity to daclizumab or infliximab. * Age less than 18 years. * Patients who are pregnant or at risk of pregnancy and unwilling to use acceptable birth control methods. * Patients with an allergy to murine products.